Search - tctmd.com

Displaying 61 - 80 of 94

Sort: Relevancy | Date

EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes

News Conference News ACC 2025

EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes

April 07, 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

News Conference News ACC 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Michael O'Riordan

March 31, 2025

Chronic HF Patients Needing CRT Fare Better With LBB Pacing: HeartSync-LBBP

News Conference News EHRA 2025

Chronic HF Patients Needing CRT Fare Better With LBB Pacing: HeartSync-LBBP

March 31, 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

March 30, 2025

What’s Going to Be Hot at ACC 2025?

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

Some Mitral TEER Patients Slipping Through the Cracks in the First Month

News Daily News

Some Mitral TEER Patients Slipping Through the Cracks in the First Month

Michael O'Riordan

March 21, 2025

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

News Daily News

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

March 21, 2025

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

Patient-Centric Outcomes Embraced by Global Heart Valve Experts

News Daily News

Patient-Centric Outcomes Embraced by Global Heart Valve Experts

February 24, 2025

Positive Results With Carillon Mitral Device Seen in Real-world Registries

News Conference News THT 2025

Positive Results With Carillon Mitral Device Seen in Real-world Registries

February 21, 2025

Questioning the KCCQ: Experts Debate Its Validity as QoL Metric

News Conference News THT 2025

Questioning the KCCQ: Experts Debate Its Validity as QoL Metric

February 19, 2025

HF Benefits Look Durable in Single-Arm Study of Coronary Sinus Shunt

News Conference News THT 2025

HF Benefits Look Durable in Single-Arm Study of Coronary Sinus Shunt

February 18, 2025

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

News Daily News

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

Michael O'Riordan

February 13, 2025

AIM-POWER: Remote, App-Based Intervention Boosts GDMT Use in HFrEF

News Conference News THT 2025

AIM-POWER: Remote, App-Based Intervention Boosts GDMT Use in HFrEF

February 13, 2025

Kansas City Cardiomyopathy Questionnaire: Why All the Fuss?

Presentation THT 2025

Kansas City Cardiomyopathy Questionnaire: Why All the Fuss?

Presenter: JoAnn Lindenfeld

February 13, 2025

Evidence That Challenges the Validity of KCCQ as a Measure of Quality of Life in Both Blinded and Unblinded Studies

Presentation THT 2025

Evidence That Challenges the Validity of KCCQ as a Measure of Quality of Life in Both Blinded and Unblinded Studies

Presenter: Gregg Stone

February 13, 2025

Evidence Supporting the Use of KCCQ as a Valid Measure of Quality of Life in Both Blinded and Unblinded Studies

Presentation THT 2025

Evidence Supporting the Use of KCCQ as a Valid Measure of Quality of Life in Both Blinded and Unblinded Studies

Presenter: David Cohen

February 13, 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

News Conference News THT 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

February 12, 2025

Acoramidis Approved in Europe for ATTR Cardiomyopathy

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.